Glucagon antagonists and methods relating thereto

Details Glucagon antagonists and methods relating thereto Glucagon antagonists and methods relating thereto

1994-08-10

1996-04-16

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

A61K 3121

Patent

active

055083048

ABSTRACT:
Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response pathway. The glucagon antagonists may be used within therapeutic compositions to treat disease states associate with elevated glucose levels, including diabetes and hyperglycemia. The present invention also discloses a biologically pure culture of ATCC accession number 74200, as well as methods relating to the production of glucagon antagonists by cultivating the same in a nutrient medium and recovering the glucagon antagonist therefrom.

REFERENCES:
Ueno, Y., Mycotoxins-Production, Isolation, Separation and Purification, V. Betina (Editor), 1984, Elsevier Science Publishers B.V., Amsterdam.
Stark, A. A., et al. Journal of Environmental Pathology & Toxicology, 2:313-324, 1978.
Cameron, Donald W., et al., Aust. J. Chem., 29:1535-1548, 1976.
Pal, Tarasankar and Anjali Pal, J. Indian Chem. Soc., 66: 236-238, 1989.
Franck, Bruchard, et al., Angew. Chem. Internat., 14:819-820, 1975.
Betina, Vladimir and Stefan Kuzela, Chem.-Biol. Interactions, 62:179-189, 1987.
Yanagi, Yoshikazu, et al., J. Pesticide Sci., 1:107-114, 1976.
Kawai, Kiyoshi, et al., Toxicology Letters, 20:155-160, 1984.
Santesson, Johan, Acta Chem. Scand., 24(9):3331-3334, 1970.
Gill, Melvyn and Alberto Gimenez, Phytochemistry, 30(3):951-955, 1991.
Hatfield, George M. and Daniel E. Slagle, Journal Lloydia, 36(3):354-356 (1980).
Shibata, Shoji, et al., Journal Chem. Pharm. Bull., 3:278-283, 1955.
Shibata, Shoji, et al., Journal Chem. Pharm. Bull., 6 573-575, 1957.
Kawai, K., et al., Proc. Jpn. Assoc. Mycotoxicol., 19:25-29, 1984.
Podojil, M., et al., Folia Microbiol., 23:438-443, 1979.
Mori, Hideki, et al., Cancer Research, 44:2918-2923, 1984.
Kawai, Kiyoshi, et al., Toxicology Letters, 20:155-160, 1984.
Nikaido, Tamotsu, et al., Chem. Pharm. Bull., 32(8):3075-3078, 1984.
Dobias, Jozef, et al., Biologia [Bratislava], 35(6),431-434, 1980.
Kawai, K., et al., Proc. Jap. Assoc. Mycotoxicol., 15:19-21, 1982.
Stark et al., "Mutagenicity and Antibacterial Activity of Mycotoxins Producted by Panicillium Islandicum Sopp and Penicillim Rugulosom," J. of Environ. Path. Toxicol. 2(2):313-324, 1978.
Betina et al., "Uncoupling Effect of Fungal Hydroxyanthraquinones on Mitochondrial Oxidative Phosphorylation," Chemico-Biological Interactions 62(2):179-189, 1987.
Derwent Abstract AN 81-48493 (JP 56-055334) May 1981.
Roane et al., Chem. Abs, 91:153952r, 1979.
Yanagi et al., Biol. Abs, 63(9):50978, 1976.
Cho et al., Biol. Abs, 90(9):98361, 1990.

Affiliated with

Also associated with

Rating

Glucagon antagonists and methods relating thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glucagon antagonists and methods relating thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon antagonists and methods relating thereto will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-325492